In 2022, a modified version of the GLP-1/GIP dual agonist, tirzepatide (Zepbound®), developed by Eli Lilly induced an average weight loss of 21% in humans with obesity and 15% weight loss in obese patients with diabetes (1). The gene discussed is GCG; the disease is obesity disorder.